Logo image of AXDX

ACCELERATE DIAGNOSTICS INC (AXDX) Stock Fundamental Analysis

NASDAQ:AXDX - Nasdaq - US00430H2013 - Common Stock - Currency: USD

1.19  +0.08 (+7.21%)

After market: 1.2393 +0.05 (+4.14%)

Fundamental Rating

1

Overall AXDX gets a fundamental rating of 1 out of 10. We evaluated AXDX against 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of AXDX have multiple concerns. AXDX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AXDX had negative earnings in the past year.
In the past year AXDX has reported a negative cash flow from operations.
In the past 5 years AXDX always reported negative net income.
In the past 5 years AXDX always reported negative operating cash flow.
AXDX Yearly Net Income VS EBIT VS OCF VS FCFAXDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

AXDX has a Return On Assets of -165.42%. This is amonst the worse of the industry: AXDX underperforms 91.44% of its industry peers.
Industry RankSector Rank
ROA -165.42%
ROE N/A
ROIC N/A
ROA(3y)-128.73%
ROA(5y)-106.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AXDX Yearly ROA, ROE, ROICAXDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K

1.3 Margins

Looking at the Gross Margin, with a value of 24.25%, AXDX is doing worse than 79.68% of the companies in the same industry.
AXDX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AXDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.13%
GM growth 5Y-6.67%
AXDX Yearly Profit, Operating, Gross MarginsAXDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

More info and screens

1

2. Health

2.1 Basic Checks

AXDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
AXDX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AXDX has been increased compared to 5 years ago.
Compared to 1 year ago, AXDX has a worse debt to assets ratio.
AXDX Yearly Shares OutstandingAXDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
AXDX Yearly Total Debt VS Total AssetsAXDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

AXDX has an Altman-Z score of -33.69. This is a bad value and indicates that AXDX is not financially healthy and even has some risk of bankruptcy.
AXDX has a worse Altman-Z score (-33.69) than 89.84% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -33.69
ROIC/WACCN/A
WACC5.56%
AXDX Yearly LT Debt VS Equity VS FCFAXDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

AXDX has a Current Ratio of 1.50. This is a normal value and indicates that AXDX is financially healthy and should not expect problems in meeting its short term obligations.
AXDX has a Current ratio of 1.50. This is in the lower half of the industry: AXDX underperforms 76.47% of its industry peers.
AXDX has a Quick Ratio of 1.34. This is a normal value and indicates that AXDX is financially healthy and should not expect problems in meeting its short term obligations.
AXDX's Quick ratio of 1.34 is on the low side compared to the rest of the industry. AXDX is outperformed by 65.78% of its industry peers.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.34
AXDX Yearly Current Assets VS Current LiabilitesAXDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

AXDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.19%, which is quite impressive.
Looking at the last year, AXDX shows a decrease in Revenue. The Revenue has decreased by -0.75% in the last year.
The Revenue has been growing by 16.29% on average over the past years. This is quite good.
EPS 1Y (TTM)34.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-521.43%
Revenue 1Y (TTM)-0.75%
Revenue growth 3Y2.59%
Revenue growth 5Y16.29%
Sales Q2Q%-9.82%

3.2 Future

Based on estimates for the next years, AXDX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.24% on average per year.
The Revenue is expected to decrease by -0.65% on average over the next years.
EPS Next Y36.25%
EPS Next 2Y20.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-4.51%
Revenue Next 2Y-0.65%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AXDX Yearly Revenue VS EstimatesAXDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
AXDX Yearly EPS VS EstimatesAXDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AXDX. In the last year negative earnings were reported.
Also next year AXDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AXDX Price Earnings VS Forward Price EarningsAXDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXDX Per share dataAXDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

AXDX's earnings are expected to grow with 20.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.24%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AXDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACCELERATE DIAGNOSTICS INC

NASDAQ:AXDX (2/21/2025, 8:02:29 PM)

After market: 1.2393 +0.05 (+4.14%)

1.19

+0.08 (+7.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners18.91%
Inst Owner Change-95.92%
Ins Owners4.32%
Ins Owner Change0.03%
Market Cap29.80M
Analysts85.71
Price TargetN/A
Short Float %2.97%
Short Ratio7.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.77%
Min EPS beat(2)-23.07%
Max EPS beat(2)5.53%
EPS beat(4)1
Avg EPS beat(4)-16.36%
Min EPS beat(4)-28.08%
Max EPS beat(4)5.53%
EPS beat(8)4
Avg EPS beat(8)6.15%
EPS beat(12)7
Avg EPS beat(12)6.02%
EPS beat(16)8
Avg EPS beat(16)6.14%
Revenue beat(2)0
Avg Revenue beat(2)-3.07%
Min Revenue beat(2)-3.41%
Max Revenue beat(2)-2.74%
Revenue beat(4)0
Avg Revenue beat(4)-5.74%
Min Revenue beat(4)-13.88%
Max Revenue beat(4)-2.74%
Revenue beat(8)1
Avg Revenue beat(8)-8.52%
Revenue beat(12)2
Avg Revenue beat(12)-6.49%
Revenue beat(16)2
Avg Revenue beat(16)-10.34%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-8.7%
EPS NQ rev (3m)-8.7%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.48%
Revenue NQ rev (1m)-2.59%
Revenue NQ rev (3m)-2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.5
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.81
EYN/A
EPS(NY)-2.04
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.48
BVpS-1.94
TBVpS-1.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -165.42%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24.25%
FCFM N/A
ROA(3y)-128.73%
ROA(5y)-106.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.13%
GM growth 5Y-6.67%
F-Score3
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.03%
Cap/Sales 5.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.5
Quick Ratio 1.34
Altman-Z -33.69
F-Score3
WACC5.56%
ROIC/WACCN/A
Cap/Depr(3y)24.65%
Cap/Depr(5y)26.4%
Cap/Sales(3y)6%
Cap/Sales(5y)6.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-521.43%
EPS Next Y36.25%
EPS Next 2Y20.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.75%
Revenue growth 3Y2.59%
Revenue growth 5Y16.29%
Sales Q2Q%-9.82%
Revenue Next Year-4.51%
Revenue Next 2Y-0.65%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.42%
OCF growth 3YN/A
OCF growth 5YN/A